dronabinol has been researched along with Coronavirus Infections in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Blagev, DP; Callahan, SJ; Collingridge, DS; Dean, NC; Guidry, DW; Harris, D; Lanspa, MJ | 1 |
Cai, G; F K Alghetaa, H; Miranda, K; Mohammed, A; Nagarkatti, M; Nagarkatti, P; P Singh, N; Putluri, N; Wilson, K | 1 |
2 other study(ies) available for dronabinol and Coronavirus Infections
Article | Year |
---|---|
Diagnosing EVALI in the Time of COVID-19.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Betacoronavirus; Bronchoscopy; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Diagnosis, Differential; Dronabinol; Electronic Nicotine Delivery Systems; Female; Humans; Influenza, Human; Intensive Care Units; Lung; Lung Injury; Male; Middle Aged; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed; Vaping; Young Adult | 2020 |
Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
Topics: Aged; Animals; Apoptosis; Betacoronavirus; Bronchoalveolar Lavage Fluid; Cannabinoid Receptor Agonists; Coronavirus Infections; COVID-19; Cytokines; Dronabinol; Enterotoxins; Female; Humans; Lung; Male; Mice; Mice, Inbred C3H; MicroRNAs; Middle Aged; Pandemics; Pneumonia; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Signal Transduction | 2020 |